Evaluating Ingavirin Forte Capsules at Different Doses for Treating Influenza and Other Acute Respiratory Viral Infections in Adults Aged 18 to 65

What this Trial Is About

Researchers are studying the effects of Ingavirin Forte capsules at different doses compared to the standard Ingavirin capsules and placebo in adults with influenza or other acute respiratory viral infections ARVIs. This Phase 2 trial aims to evaluate how well these treatments work, their safety, and how well patients tolerate them. Participants include adults aged 18 to 65 with confirmed influenza or ARVIs, showing significant symptoms and meeting specific clinical criteria. Participants are randomly assigned to one of five groups three groups receive Ingavirin Forte capsules at varying doses 90 mg plus either 5 mg, 10 mg, or 20 mg, one group receives standard Ingavirin 90 mg capsules, and one group receives a placebo. All treatments are taken as one capsule twice daily morning and evening for five consecutive days under double-blind conditions. During the 10-day study period, participants are monitored closely with visits on Days 3 and 6 to assess symptom severity, use of nasal sprays and pain medications, and viral elimination. Researchers measure the time until all symptoms resolve without additional medications and evaluate treatment effectiveness through clinical assessments and patient feedback. Safety and tolerability are also assessed throughout the trial, which may continue until the end of 2027.

Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.